Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension
Continuous Innovation: Locus GameChain Enters Commercialization Stage with Serverless Gaming Solution
No KYC. 100x Leverage. $50 Welcome Bonus. Crypto Futures Trading Made Easy on BexBack.
New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease...
